Biotech | April 13, 2022
Novel Covid-19 vaccine may protect the immunocompromised
The peptide-based vaccine induces a t cell-dependent response
The peptide-based vaccine induces a t cell-dependent response
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
The total investment is in the region of Rs 200 crore
Both companies have been selected for stand-by production by German government
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Subscribe To Our Newsletter & Stay Updated
